Randomized, double-blind, sponsor-open, phase 1b study to assess the safety, pharmacokinetics and to explore the pharmacodynamics of RO7486967 in patients with moderate to severe active ulcerative colitis
Latest Information Update: 22 Nov 2023
At a glance
- Drugs Selnoflast (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 04 Jul 2022 Status changed from active, no longer recruiting to completed.
- 11 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2021 Status changed from not yet recruiting to recruiting.